Overview

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer